Published in Cell Cycle on February 01, 2012
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem (2002) 3.34
Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell (2007) 3.02
Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res (2007) 2.97
Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest (2011) 2.32
FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J (2004) 2.24
Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res (2006) 2.16
Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res (2003) 2.01
Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics (2005) 1.96
Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool. Gastroenterology (2011) 1.86
ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell (2002) 1.86
Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell (2003) 1.81
CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology (2002) 1.62
Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res (2007) 1.53
Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res (2003) 1.46
COMMD1 disrupts HIF-1alpha/beta dimerization and inhibits human tumor cell invasion. J Clin Invest (2010) 1.28
Cervical cancer. J Natl Compr Canc Netw (2013) 1.24
Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Res (2005) 1.23
Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol (2003) 1.20
Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers. Proteomics (2004) 1.15
Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol (2002) 1.14
Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia (2008) 1.08
Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res (2011) 1.07
Cervical cancer. J Natl Compr Canc Netw (2010) 1.07
Sox9 induction, ectopic Paneth cells, and mitotic spindle axis defects in mouse colon adenomatous epithelium arising from conditional biallelic Apc inactivation. Am J Pathol (2013) 1.07
IRS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRS1 to the neoplastic phenotype. J Biol Chem (2009) 1.05
Drosophila split ends homologue SHARP functions as a positive regulator of Wnt/beta-catenin/T-cell factor signaling in neoplastic transformation. Cancer Res (2007) 1.03
Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol (2013) 1.01
Loss of estrogen receptor 1 enhances cervical cancer invasion. Am J Pathol (2010) 1.01
Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression. Oncogene (2003) 1.00
Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Res (2008) 0.98
A 2-D liquid separations/mass mapping method for interlysate comparison of ovarian cancers. Anal Chem (2002) 0.98
A model-based scan statistic for identifying extreme chromosomal regions of gene expression in human tumors. Bioinformatics (2005) 0.96
Classifications of ovarian cancer tissues by proteomic patterns. Proteomics (2006) 0.94
A protein molecular weight map of ES2 clear cell ovarian carcinoma cells using a two-dimensional liquid separations/mass mapping technique. Electrophoresis (2002) 0.94
Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw (2014) 0.93
Classification of cancer cell lines using an automated two-dimensional liquid mapping method with hierarchical clustering techniques. Mol Cell Proteomics (2005) 0.93
Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res (2010) 0.93
Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2009) 0.93
Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res (2005) 0.92
Current challenges and opportunities for research on borderline ovarian tumors. Hum Pathol (2004) 0.90
Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. Am J Pathol (2003) 0.90
Cervical cancer. J Natl Compr Canc Netw (2008) 0.83
Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma. Clin Cancer Res (2012) 0.82
Funding anatomic pathology research: a retrospective analysis of an intramural funding mechanism. Arch Pathol Lab Med (2013) 0.82
Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas. Proteomics Clin Appl (2008) 0.82
Two Distinct Categories of Focal Deletions in Cancer Genomes. PLoS One (2013) 0.82
Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage. J Proteome Res (2009) 0.81
A pilot study of microsatellite instability and endometrial cancer survival in white and African American women. Int J Gynecol Pathol (2012) 0.78
Ovarian steroid cell tumor with biallelic adenomatous polyposis coli inactivation in a patient with familial adenomatous polyposis. Genes Chromosomes Cancer (2011) 0.77
Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.77
Uterine cancers. J Natl Compr Canc Netw (2006) 0.76
Cancer: cell survival guide. Nature (2004) 0.76
Cervical cancer guidelines. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2004) 0.75
Cervical Mesonephric Adenocarcinoma With Novel FGFR2 Mutation. Int J Gynecol Pathol (2020) 0.75
Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention. Clin Obstet Gynecol (2017) 0.75
Intravascular histiocytosis presenting with extensive vulvar necrosis. J Cutan Pathol (2009) 0.75
Microscopic extraovarian sex cord proliferations: an undescribed phenomenon. Histopathology (2014) 0.75
Serous Tubal Intraepithelial Carcinoma or Not? Metastases to Fallopian Tube Mucosa Can Masquerade as In Situ Lesions. Arch Pathol Lab Med (2017) 0.75